DIMN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe sharp TTM revenue rebound indicates that customer demand and bioprocessing activity are recovering materially. If sustained, stronger volume can improve operating leverage, support renewed investment, and reinforce Sartorius Stedim Biotech’s position as a supplier embedded in biopharmaceutical production workflows.
Recurring Consumables ModelRecurring consumables create repeat purchasing linked to customers’ production batches, providing a more durable revenue base than equipment sales alone. Installed systems can also increase future demand for compatible consumables and replacement parts, supporting customer retention and longer-term account value.
Improved LeverageThe substantial reduction in debt-to-equity and larger equity base indicate a more balanced capital structure than in 2023. Improved leverage should give the company greater flexibility to fund operations and investment while reducing balance-sheet pressure during the ongoing profitability recovery.
Bears Say
Profitability Below PeakRevenue has recovered faster than profitability, leaving net and gross margins well below prior peaks. This suggests that the earnings recovery is not yet fully supported by normalized operating economics, potentially limiting internal funding capacity and reducing resilience if volume growth moderates.
Weak Free Cash Flow ConversionAlthough free cash flow growth is strong from a weak base, conversion of net income into cash remains low and operating cash flow is less consistent than revenue. Persistently weak conversion could constrain debt reduction, investment capacity, and the quality of reported earnings over coming quarters.
Sizable Debt And Modest ReturnsLeverage has improved, but the remaining debt burden is still sizable relative to the company’s currently modest returns on equity. Until profitability strengthens, interest obligations and capital tied to the balance sheet may limit returns, reduce financial flexibility, and slow the pace of recovery.
Sartorius Stedim Biotech News
DIMN FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Currently, no data Available
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is $364.26B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Oct 22, 2026 which is in 42 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Jul 23, 2026. The company reported $24.616 earnings per share for the quarter, missing the consensus estimate of $24.872 by -$0.256.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech does not currently pay dividends.
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 23.36.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of $24.616 in its last earnings report, missing expectations of $24.872. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in MX:DIMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.